用于治疗2型糖尿病和肥胖症的GLP-1单受体、双受体和三受体激动剂：一项叙述性综述

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.

作者信息

Alfaris Nasreen, Waldrop Stephanie, Johnson Veronica, Boaventura Brunna, Kendrick Karla, Stanford Fatima Cody

机构信息

Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, KSA, Saudi Arabia.

University of Colorado School of Medicine-Anschutz Medical Campus, Department of Pediatrics, Section on Nutrition and Lifestyle Medicine, Nutrition Obesity Research Center at the University of Colorado (CUNORC), Aurora, CO, USA.

出版信息

EClinicalMedicine. 2024 Aug 30;75:102782. doi: 10.1016/j.eclinm.2024.102782. eCollection 2024 Sep.

UNLABELLED

Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement. GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric emptying. The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, routes of administration, and flexibility in dosing. These agents reduce HbA1c levels, facilitate weight loss, and exhibit cardiovascular protective effects, making them an integral component of T2DM and obesity management. This review will discuss the currently approved medication for T2DM and obesity, and will also highlight the advent of novel agents which are dual and triple hormonal agonists which represent the future direction of incretin-based therapy.

FUNDING

National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).

未标注

肥胖症和2型糖尿病（T2DM）是全球主要的健康挑战，在全球范围内患病率不断上升。胰高血糖素样肽-1受体激动剂（GLP-1RAs）已成为这两种疾病的关键治疗选择，在血糖管理、体重减轻、心血管疾病预防和肾脏健康改善方面均显示出疗效。GLP-1是一种肠促胰岛素激素，在葡萄糖代谢和食欲调节中起关键作用，影响胰岛素分泌、胰岛素敏感性和胃排空。GLP-1RAs的治疗用途已显著发展，提供了多种制剂，这些制剂具有不同的疗效、给药途径和给药灵活性。这些药物可降低糖化血红蛋白（HbA1c）水平，促进体重减轻，并具有心血管保护作用，使其成为T2DM和肥胖症管理的重要组成部分。本综述将讨论目前批准用于T2DM和肥胖症的药物，并强调新型药物的出现，这些新型药物是双激素和三激素激动剂，代表了基于肠促胰岛素疗法的未来方向。